Medications that help to lower blood sugar levels and promote weight loss have emerged as a promising new option for people who struggle with their weight. These drugs, known as GLP-1 agonists, have proven to be very effective. However, like many medications, they may come with gastrointestinal (GI) side effects that can impact a patient’s comfort and adherence.
The purpose of this clinical trial is to assess the effectiveness of ARIKAYCE, inhaled once daily, in patient populations with mild and untreated MAC lung infection.
Eligible patients include those who currently have a positive MAC sputum culture and have not received treatment for their infection.
The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.
Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.
